Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lifts Gaming Realms target price following 'strong' H1

(Sharecast News) - Analysts at Canaccord Genuity reiterated their 'buy' rating on Gaming Realms and raised its target price to 67p from 57p on Monday, citing a strong first-half performance and accelerating international momentum. Canaccord Genuity highlighted 18% revenue growth to £16m in H125, with adjusted underlying earnings up 30% to £7.5m and net cash rising £5.5m to £19.0m. Licensing revenue climbed 22% to £14.1m, driven by six new Slingo titles and 19 additional operator launches. Brand licensing surged to £2.6m from £0.3m, while social publishing dipped 7%.

Despite UK content licensing falling 13% in H1 and 21% in Q2 due to April's staking limit regulations, Canaccord noted a sharp recovery in July and August as new game formats gained traction. Management expects UK revenues to normalise by year-end.

Licensing revenue rose 2% in the first two months of H2, which the Canadian bank deemed satisfactory given FX headwinds and UK regulatory drag.

Canaccord Genuity also said the current CY25E/26E enterprise value/EBITDA multiples of 8.4x/6.8x undervalue the group's growth profile and increasing North American exposure, and that its new target price was based on a rolled-forward CY26E PER of 10x.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.